Program
ALN-CIDEB
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Liver Diseases, Alcoholic · Obesity, led by Regeneron Pharmaceuticals.
Furthest: phase 3, since Sep 28, 20264 company-led studies, 4 open or runningNext primary completion: Aug 17, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 44 open or running | phase 3since Sep 28, 2026 | Feb 14, 2025 | Aug 17, 2027phase 2 · NCT06836609 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 14, 2025First study: phase 2 study in ObesityFirst studyNCT06836609 · 118 enrolled · United States, United Kingdom
- Jun 1, 2026Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT07631637 · 360 planned · United States, Puerto Rico, United Kingdom
- Sep 28, 2026Phase 3 study in Non-alcoholic Fatty Liver DiseasePhase 3 reachedNCT07854782 · 1,500 planned · United States
- Nov 5, 2026Phase 2 study in Liver Diseases, AlcoholicNCT07933328 · 120 planned
Ahead
- Aug 17, 2027Primary completion: phase 2 study in ObesityNCT06836609
- Jan 29, 2029Primary completion: phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT07631637
- Mar 3, 2029Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT07854782
- May 7, 2029Primary completion: phase 2 study in Liver Diseases, AlcoholicNCT07933328
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07933328Liver Diseases, Alcoholic | 2 | Not yet recruiting | May 7, 2029 | 120 |
| NCT07854782Non-alcoholic Fatty Liver Disease · United States | 3 | Recruiting | Mar 3, 2029 | 1,500 |
| NCT07631637Non-alcoholic Fatty Liver Disease · United States, Puerto Rico, United Kingdom | 2 | Recruiting | Jan 29, 2029 | 360 |
| NCT06836609Obesity · United States, United Kingdom | 2 | Active, not recruiting | Aug 17, 2027 | 118 |
How it is read
Names in the registry
- “ALN-CIDEB”, 4 entries
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 2 studies
- Liver Diseases, Alcoholic, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.